Latest News

FDA approves PET imaging product Gozellix for prostate cancer
FDA approves PET imaging product Gozellix for prostate cancer

March 20th 2025

Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.

Trial launches of CBP/p300 inhibitor in mCRPC
Trial launches of CBP/p300 inhibitor in mCRPC

March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population
Nadofaragene firadenovec maintains safety, efficacy in real-world population

March 20th 2025

Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

March 19th 2025

Real-world data reaffirm oncologic benefits of BLC for NMIBC
Real-world data reaffirm oncologic benefits of BLC for NMIBC

March 19th 2025

Latest Videos

Latest News

© 2025 MJH Life Sciences

All rights reserved.